Article Text

Download PDFPDF
Systematic review with meta-analysis
Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease
  1. Robert Sidney Rosenson
  1. Department of Medicine/Cardiology, Mount Sinai School of Medicine, New York, New York, USA
  1. Correspondence to : Robert Sidney Rosenson
    Department of Medicine/Cardiology, Mount Sinai School of Medicine, 1425 Madison Ave, MC1—Freedom Trials Office, New York, NY 10029, USA, robert.rosenson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Current guideline-based eligibility criteria for the statin therapy have incorporated estimates of risk reduction from randomised clinical trials of primary prevention in which individuals have been treated from an average 1.5–5 years, cost of treatment before the recent generic availability of potent statin agents, and potential harm associated with the use of treatment in a low-risk individual. Statins have been advocated for the primary prevention of cardiovascular disease (CVD) in patients with an estimated 5-year major CVD event risk ≥ 10%.1–3 The debate concerning the risks and benefits of the statin …

View Full Text


  • Competing interests None.